Black Hills Eye Institute

Rapid City, South Dakota 57701

0 studies enrolling now · 12 studies all time

What they study most

Branch Retinal Vein Occlusion, Central Retinal Vein Occlusion, Diabetic Macular Edema, Dry Eye, Geographic Atrophy, Hemiretinal Vein Occlusion, Macular Degeneration, Macular Edema, Neovascular Age-related Macular Degeneration, Primary Sjögren Syndrome, Wet Macular Degeneration

Studies at this site

• A Study to Investigate Faricimab Treatment Response in Treatment-Naive, Underrepresented Patients With Diabetic Macular Edema — Running, not enrolling
• A Study to Investigate Vamikibart (RO7200220) in Diabetic Macular Edema — Completed
• A Study to Evaluate the Long-Term Safety and Tolerability of Faricimab in Participants With Neovascular Age-Related Macular Degeneration — Completed
• A Study to Evaluate the Efficacy and Safety of Faricimab in Participants With Neovascular Age-Related Macular Degeneration (TENAYA) — Completed
• A Study to Evaluate the Efficacy and Safety of Faricimab (RO6867461) in Participants With Diabetic Macular Edema (YOSEMITE) — Completed
• A Study to Evaluate the Efficacy and Safety of Faricimab in Participants With Macular Edema Secondary to Branch Retinal Vein Occlusion — Completed
• A Study to Evaluate the Efficacy and Safety of Faricimab in Participants With Macular Edema Secondary to Central Retinal or Hemiretinal Vein Occlusion — Completed
• Lacripep™ in Subjects With Dry Eye Associated With Primary Sjögren's Syndrome — Completed
• A Study Investigating the Safety and Efficacy of Lampalizumab Intravitreal Injections in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration — Stopped early
• Long-Term Safety of Lampalizumab Intravitreal (ITV) Injections in Participants With Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration (OMASPECT) — Stopped early
• Ranibizumab for Edema of the Macula in Diabetes: Protocol 3 With High Dose - the READ 3 Study — Completed
• Safety and Efficacy Study of Small Interfering Ribonucleic Acid (RNA) Molecule (Cand5) to Treat Wet Age-Related Macular Degeneration — Completed